VSTM

Verastem, Inc.

7.46 USD

Last updated Sep 1, 18:02 UTC

Yesterday HIGH

$7.32

Yesterday LOW

$7

52w HIGH

$11.24

52w LOW

$3.43

EPS

-0.35

PE

-21.31

Next Earnings

Nov 3, 2026

Overview News Unusual Options Flow Insider Transactions Government Trades Fundamentals

Verastem, Inc. stock is up 31.11% since 30 days ago. The next earnings date is Nov 3, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 28.57% of the previous 14 September’s closed higher than August. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

06 Jul 14:14	18 Sep, 2026	3.00	CALL	196	406
06 Jul 16:37	15 Jan, 2027	5.00	CALL	1385	586
06 Jul 16:37	15 Jan, 2027	10.00	CALL	1385	467
13 Jul 17:00	15 Jan, 2027	10.00	CALL	500	2348
14 Jul 16:58	18 Sep, 2026	7.00	CALL	3000	66
23 Jul 17:39	18 Sep, 2026	8.00	CALL	1000	33
30 Jul 15:46	15 Jan, 2027	8.00	CALL	136	207
30 Jul 16:50	15 Jan, 2027	8.00	CALL	162	207
31 Jul 14:51	15 Jan, 2027	8.00	CALL	883	505
14 Aug 16:16	18 Dec, 2026	5.00	PUT	200	127

Advanced Data Unlock

Benzinga Newsdesk

Thu May 14, 2026

Mizuho Maintains Outperform on Verastem, Lowers Price Target to $14

Mizuho analyst Graig Suvannavejh maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $16 to $14.
Benzinga Newsdesk

Fri May 8, 2026

Verastem shares are trading lower after the company reported worse-than-expected Q1 sales results. Also, BTIG lowered its price target on the stock from $19 to $18.
Benzinga Newsdesk

Fri May 8, 2026

BTIG Maintains Buy on Verastem, Lowers Price Target to $18

BTIG analyst Jeet Mukherjee maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price target from $19 to $18.
Benzinga Newsdesk

Thu May 7, 2026

Verastem Q1 Adj. EPS $(0.43) Beats $(0.46) Estimate, Sales $18.671M Miss $21.579M Estimate

Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.46) by 6.52 percent. This is a 45.57 percent increase over losses of $(0.79) per share from the same
Benzinga Newsdesk

Thu Apr 30, 2026

Verastem Oncology Rolls Out Its Reimagine Recurrent Low-Grade Serous Ovarian Cancer Campaign For AVMAPKI FAKZYNJA CO-PACK

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the launch of its Reimagine Recurrent Low-Grade Serous
Benzinga Newsdesk

Thu Apr 23, 2026

BTIG Reiterates Buy on Verastem, Maintains $19 Price Target

BTIG analyst Jeet Mukherjee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $19 price target.
Benzinga Newsdesk

Mon Apr 20, 2026

BTIG Reiterates Buy on Verastem, Maintains $19 Price Target

BTIG analyst Jeet Mukherjee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $19 price target.
Benzinga Newsdesk

Fri Apr 10, 2026

BTIG Reiterates Buy on Verastem, Maintains $19 Price Target

BTIG analyst Jeet Mukherjee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $19 price target.
Benzinga Newsdesk

Fri Apr 10, 2026

HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $18 price target.
Benzinga Newsdesk

Fri Apr 10, 2026

Verastem Oncology Reports Two Year Follow Up Data Showing Durable Response And Safety For Avutometinib Plus Defactinib In Recurrent LGSOC At SGO 2026

Mizuho

Tue Aug 11, 13:47

buy

confirm
Guggenheim

Fri Aug 7, 18:45

buy

confirm